CONNECT WITH US
AI & Deeptech

AI & Deeptech

OpenAI acquires drug platform to tackle worst delays keeping medicines from patients

Interesting Engineering – AI & Robotics logo

Published on

Add as a preferred source on Google
OpenAI acquires drug platform to tackle worst delays keeping medicines from patients

Getting a new medicine to patients can take more than a decade. OpenAI wants to tackle some of the work behind that lengthy process, using AI agents to help pharmaceutical teams manage drug development programs.

The company has acquired Orchestra Bio, a platform that helps drugmakers coordinate development work. Its team and technology will join Rosalind, OpenAI’s initiative for life sciences research.

Developing a medicine in the United States typically takes 10 to 15 years, from identifying a promising biological target to securing regulatory approval. Scientific research is only part of the challenge. Even promising discoveries can face delays when development teams struggle to keep complex projects on track.

OpenAI’s Rosalind initiative helps scientists investigate questions in biology and chemistry. Its GPT-Rosalind model supports scientific reasoning, while Rosalind Workbench connects researchers with scientific tools and data.

We’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development.

Together, we’ll build on Rosalind, our AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients…

Orchestra brings a different capability to the mix. Its platform helps teams oversee the work required to advance a potential medicine, giving program leaders a clearer picture of progress across a drug’s development.

Consider a failed manufacturing batch. The setback could force a pharmaceutical company to postpone a clinical trial. Teams must then work out which milestones need to move and whether they can limit the disruption.

Orchestra’s AI agents can collect relevant information and identify the activities affected by such problems.


Source link
Related Topics:AI & Deeptech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.